A Phase 2 Study to Evaluate the Effect of EDG-5506 on Safety, Pharmacokinetics, and Biomarkers in Children and Adolescents With Duchenne Muscular Dystrophy Previously Treated With Gene Therapy

Trial ID: NCT06100887

Interventional - Phase 2 - Active, not recruiting

The FOX study is a 2-part, multicenter, Phase 2 study of safety, pharmacokinetics, and biomarkers in children and adolescents with Duchenne muscular dystrophy previously treated with gene therapy including a randomized, double-blind, placebo-controlled Part A, followed by an open-label part B.

Conditions

Duchenne Muscular Dystrophy

Interventions

Sevasemten Dose 1
Sevasemten Dose 2
Sevasemten Dose 3
Placebo

Eligibility

Inclusion criteria

Aged 6 to 17 with a documented mutation on the DMD gene and phenotype consistent with DMD.
Prior receipt of an AAV-based gene therapy (≥ 2 years after documented receipt of gene therapy administration or ≥ 3 years after randomization in a randomized study).
Able to complete stand from supine in ≤ 8 seconds at the Screening visit and able to perform the 4-stair climb in \< 10 seconds at the Screening visit.
Body weight ≥ 15 kg at the Screening visit.
Treatment with a stable dose of corticosteroids for a minimum of 6 months prior to the Baseline visit.
Key

Exclusion criteria

Medical history or clinically significant physical exam/laboratory result that, in the opinion of the investigator, would render the participant unsuitable for the study. This includes venous access that would be too difficult to facilitate repeated blood sampling.
Screening visit cardiac echocardiography showing left ventricular ejection fraction (LVEF) \< 40%.
Receipt of an investigational drug (other than the AAV-based gene therapy per Inclusion criteria) within 30 days or 5 half-lives (whichever is longer) of the Screening visit in the present study.
Receipt of an exon-skipping therapy within 6 months prior to the Screening visit.

Sponsor

Edgewise Therapeutics, Inc.

Source: ClinicalTrials.gov

Search more clinical trials on myTomorrows